Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists

Pituitary

Volumn 14, Issue 3, 2011, Pages 222-230

  Babey, Muriel ^a,b   Sahli, Rahel ^a   Vajtai, Istvan ^a   Andres, Robert H ^a   Seiler, Rolf W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine agonists; Hyperprolactinemia; Macroprolactinomas; Microprolactinomas; Pituitary surgery; Prolactin; Prolactinomas

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; IMPOTENCE; INAPPROPRIATE VASOPRESSIN SECRETION; LIBIDO DISORDER; MALE; NASAL SYNECHIA; PRIORITY JOURNAL; PROLACTINOMA; REMISSION; RETROSPECTIVE STUDY; SWITZERLAND; TISSUE ADHESION; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

ADOLESCENT; ADULT; DOPAMINE AGONISTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; PROLACTINOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053925397     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-010-0283-y     Document Type: Article

References (61)

1. Molitch ME (1999) Medical treatment of prolactinomas. Endo-crinol Metab Clin North Am 28(1):143-169 (Pubitemid 29164782)
2. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65(2):265-273 (Pubitemid 44079693)
3. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485-534 (Pubitemid 44213229)
4. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2009) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43-51
5. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518-2522
6. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM et al (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63(1):26-31 (Pubitemid 40966398)
7. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22(5):354-359 (Pubitemid 29259557)
8. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G (1997) Use of cabergoline in the long-term treatment of hy-perprolactinemic and acromegalic patients. J Endocrinol Invest 20(9):537-546 (Pubitemid 28014506)
9. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and non tumoral hyperprolactinemia. N Engl J Med 349(21):2023-2033 (Pubitemid 37448925)
10. Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428-2436
11. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356(1):39-46 (Pubitemid 46041752)
12. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29-38 (Pubitemid 46041751)
13. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neu-rol 6(9):826-829 (Pubitemid 47243713)
14. Amar AP, Couldwell WT, Chen JC, Weiss MH (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 97(2):307-314 (Pubitemid 34827330)
15. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11-18 (Pubitemid 351211035)
16. Turner HE, Adams CB, Wass JA (1999) Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopa-mine agonists? Eur J Endocrinol 140(1):43-47 (Pubitemid 29074766)
17. Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1999) Transsphenoidal microsurgical therapy of prolacti-nomas: initial outcomes and long-term results. Neurosurgery 44(2):254-261 (discussion 61-63)
18. Buchfelder M (2005) Treatment of pituitary tumours: surgery. Endocrine 28(1):67-75
19. Couldwell WT (2004) Transsphenoidal and transcranial surgery for pituitary adenomas. J Neurooncol 69(1-3):237-256 (Pubitemid 39256133)
20. Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M et al (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215(2):463-469 (Pubitemid 30237846)
21. Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neuro 16:185-217
22. Jane JA Jr, Thapar K, Kaptain GJ, Maartens N, Laws ER Jr (2002) Pituitary surgery: transsphenoidal approach. Neurosurgery 51(2):435-442 (discussion 42-44)
23. Buchfelder M, Schlaffer S (2009) Surgical treatment of pituitary tumours. Best Pract Res Clin Endocrinol Metab 23(5):677-692
24. Saeger W, Dea E et al (2004) Prolactin producing adenoma
25. Saeger W, Mohr K, Caselitz J, Ludecke DK (1986) Light and electron microscopical morphometry of pituitary adenomas in hyperprolactinemia. Pathol Res Pract 181(5):544-550 (Pubitemid 17211067)
26. Barker FG II, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumours in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709-4719 (Pubitemid 37357516)
27. Sudhakar N, Ray A, Vafidis JA (2004) Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br J Neurosurg 18(5):507-512 (Pubitemid 40076198)
28. Cappabianca P, Cavallo LM, de Divitiis O, Solari D, Esposito F, Colao A (2008) Endoscopic pituitary surgery. Pituitary 11(4):385-390
29. Kuroki A, Kayama T (2002) Endoscopic approach to the pituitary lesions: contemporary method and review of the literature. Bio-med Pharmacother 56(Suppl 1):158s-164s (Pubitemid 35448039)
30. White DR, Sonnenburg RE, Ewend MG, Senior BA (2004) Safety of minimally invasive pituitary surgery (MIPS) compared with a traditional approach. Laryngoscope 114(11):1945-1948 (Pubitemid 39539852)
31. Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB (1996) Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 81(5):1711-1719
32. Webster J, Page MD, Bevan JS, Richards SH, Douglas-Jones AG, Scanlon MF (1992) Low recurrence rate after partial hypophy-sectomy for prolactinoma: the predictive value of dynamic pro-lactin function tests. Clin Endocrinol (Oxf) 36(1):35-44
33. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87(7):3180-3186 (Pubitemid 34816362)
34. Rodman EF, Molitch ME, Post KD, Biller BJ, Reichlin S (1984) Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. JAMA 252(7):921-924 (Pubitemid 14058289)
35. Massoud F, Serri O, Hardy J, Somma M, Beauregard H (1996) Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surg Neurol 45(4):341-346 (Pubitemid 26117242)
36. Schlechte JA, Sherman BM, Chapler FK, VanGilder J (1986) Long term follow-up of women with surgically treated prolactin-secreting pituitary tumours. J Clin Endocrinol Metab 62(6):1296-1301 (Pubitemid 16085295)
37. Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309(5):280-283 (Pubitemid 13074919)
38. Thomson JA, Gray CE, Teasdale GM (2002) Relapse of hyper-prolactinemia after transsphenoidal surgery for microprolactino-ma: lessons from long-term follow-up. Neurosurgery 50(1):36-39 (discussion 9-40) (Pubitemid 41672552)
39. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102-2107 (Pubitemid 27287568)
40. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331(14):904-909 (Pubitemid 24299871)
41. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA et al (1996) Treatment of prolactin-secreting mac-roadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81(6):2338-2343 (Pubitemid 26175965)
42. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R et al (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256-5261 (Pubitemid 33070245)
43. Jahnichen S, Horowski R, Pertz HH (2005) Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513(3):225-228 (Pubitemid 40616066)
44. Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356(1):6-9
45. Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159(4):363-367
46. Valassi E, Klibanski A, Biller BM (2010) Clinical review#: potential cardiac valve effects of dopamine agonists in hyper-prolactinemia. J Clin Endocrinol Metab 95(3):1025-1033
47. Molitch ME (2008) The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 93(12):4643-4645
48. Vallette S, Serri K, Serri O (2009) Cabergoline therapy for pro-lactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8(1):49-54
49. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Mar-tino E (2008) Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31(12):1119-1123
50. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M et al (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93(10):3777-3784
51. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA et al (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93(9):3348-3356
52. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D et al (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159(1):1-5 (Pubitemid 351969123)
53. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL (2008) Low dose cabergoline for hyperprolactinemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159(4):R11-R14
54. Molitch ME (1985) Pregnancy and the hyperprolactinemic woman. N Engl J Med 312(21):1364-1370 (Pubitemid 15118299)
55. Molitch ME (1999) Management of prolactinomas during pregnancy. J Reprod Med 44(12 Suppl):1121-1126 (Pubitemid 30030170)
56. Bronstein MD (2005) Prolactinomas and pregnancy. Pituitary 8(1):31-38 (Pubitemid 44680083)
57. Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinemic women. Clin Endocrinol (Oxf) 73(2):236-242
58. Yin P, Arita J (2000) Differential regulation of prolactin release and lactotrope proliferation during pregnancy, lactation and the estrous cycle. Neuroendocrinology 72(2):72-79
59. Colao A, Abs R, Barcena DG, Chanson P, Paulus W, Kleinberg DL (2008) Pregnancy outcomes following cabergoline treatment: extended results from a 12 year observational study. Clin Endo-crinol (Oxf) 68(1):66-71 (Pubitemid 350243483)
60. Molitch ME (2010) Prolactinomas and pregnancy. Clin Endo-crinol (Oxf) 73(2):147-148
61. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A et al (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16(6):791-793 (Pubitemid 35278500)